Urovant Sciences® Announces Collaboration with Holly Robinson Peete to Help Raise Awareness for Overactive Bladder and Treatment Options

Urovant Sciences, Inc., and Holly Robinson Peete Collaborate to Bring Awareness to Overactive Bladder (OAB) Symptoms and Management Options as Part of the Time To Go™ Campaign Holly Robinson Peete Shares Her Experience Living with OAB and How Her Symptoms Have Improved Since Taking GEMTESA Approximately 33 Million Americans Experience Symptoms of OAB, Which Can […]

Urovant Sciences Announces Publication of Pharmacokinetic Data on GEMTESA® (Vibegron 75mg) Administered as an Intact or Crushed Tablet

A new peer-reviewed journal paper suggests that crushing GEMTESA (vibegron) 75-mg and taking it with applesauce may be an appropriate option for people with overactive bladder (OAB) and concommitant swallowing difficulties. Results from this Phase 1 study show that vibegron can be crushed and mixed with applesauce with no clinically meaningful change to pharmacokinetic (PK) […]

Urovant Sciences® Receives “Best in Category” Award for Abstract Highlighting Investigational Novel Gene Therapy, URO-902, Presented at 2022 International Continence Society Conference

Interim 12-week analysis from the ongoing Phase 2a trial of an investigational novel gene therapy product, URO-902 (plasmid human cDNA encoding maxi-K channel), receives International Continence Society (ICS) recognition for “Best in Category Prize: Overactive Bladder.” Analysis from the trial suggests that URO-902 may be an effective, safe, and well tolerated treatment option in women […]

The Impact of Urinary Incontinence Related to Overactive Bladder on Long-Term Care Residents and Facilities in the U.S. Highlighted in New Survey

July 13, 2022 at 8:00am PST Survey of 71 Directors of Nursing (DONs) highlights a need for improved awareness, education, and management of urinary incontinence (UI) related to overactive bladder (OAB) in long-term care (LTC) settings, according to this peer-reviewed journal paper. Surveyed DONs reported an average of 62% of their residents had UI, with 81% of […]

Urovant Sciences® Named One of 2022 “Best Places to Work” in Orange County

July 7, 2022 at 8:07am PST  This is Urovant’s second year in a row to earn this recognition by Orange County Business Journal Urovant has also received a 2022 global Great Place to Work™ certification. The culmination of these two awards reflects the company’s people focused culture and underscores the opinion of employees, dedicated to improving […]

Urovant Sciences and Pierre Fabre Médicament Enter into Exclusive License Agreement to Commercialize Vibegron for the Treatment of Overactive Bladder in the European Economic Area, UK, and Switzerland

July 5, 2022 at 8:05am EST Pierre Fabre Médicament SAS (Pierre Fabre) to register and commercialize vibegron for the treatment of Overactive Bladder (OAB) in the European Economic Area, UK, and Switzerland. Urovant Sciences GmbH to receive compensation of up to USD $75 million in upfront payment, regulatory, and sales milestones as well as royalties […]

Urovant Sciences® Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association Meeting

May 15, 2022 at 10:00 AM EDT New analyses of data from the Phase 3 EMPOWUR Extension Study of GEMTESA® (vibegron) 75 mg provided additional insight into the long-term durability of the product. These data were featured in podium presentations PD 38-11 and PD 38-12: In a subgroup analysis of adults, 65 years old or above […]

Urovant Sciences® Presents Interim Data from Phase 2a Study of Investigational Novel Gene Therapy, URO-902, Supporting Safety, Tolerability, and Efficacy Endpoints at 2022 American Urological Association Meeting

May 13, 2022 at 11:30 PM CDT Interim 12-week analysis from an ongoing Phase 2a trial of an investigational novel gene therapy product (plasmid human cDNA encoding maxi-K channel) showed clinically relevant improvement in the common symptoms of overactive bladder (OAB) compared to placebo. (Plenary Presentation PLLBA-03) In this prespecified 12-week analysis of a Phase 2a […]